Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2005-01-04
2005-01-04
Wehbé, Anne Marie S. (Department: 1632)
Chemistry: molecular biology and microbiology
Vector, per se
C435S325000, C435S455000, C435S456000, C435S069100, C514S04400A, C424S199100
Reexamination Certificate
active
06838279
ABSTRACT:
Disclosed is an HSV-1-derived vector containing a DNA having a functional LAT promoter, or operative fragment thereof, a deletion in both copies of the HSV-1 LAT gene, and a deletion in both copies of the HSV-1 ICP34.5 gene. The HSV-1-derived vectors are non-neurovirulent and do not spontaneously reactivate from latency, and they optionally contain a functional HSV thymidine kinase gene, which can enhance the effectiveness against cancer of drug treatment with gancyclovir or acyclovir. Alternatively, the HSV-1-derived vectors contain at least one transcriptional unit of a LAT promoter sequence operatively linked to a nucleic acid encoding a preselected protein. In some embodiments, the preselected protein is a nucleotide sequence encoding a polypeptide toxic for cells expressing the vector, for example, human interferon-γ. Also, disclosed are kits for expressing in a mammalian cell a gene encoding a preselected protein, and mammalian cells containing the HSV-derived vectors.
REFERENCES:
patent: 4769331 (1988-09-01), Roizman et al.
patent: 4859587 (1989-08-01), Roizman
patent: 5112596 (1992-05-01), Malfroy-Camine
patent: 5268164 (1993-12-01), Kozarich et al.
patent: 5288641 (1994-02-01), Roizman
patent: 5328688 (1994-07-01), Roizman
patent: 5434137 (1995-07-01), Black
patent: 5527778 (1996-06-01), Black
patent: 5585096 (1996-12-01), Martuza et al.
patent: 5599691 (1997-02-01), Roizman
patent: 5670477 (1997-09-01), Poduslo et al.
patent: 5728379 (1998-03-01), Martuza et al.
patent: 6193980 (2001-02-01), Efstathiou
patent: 6340673 (2002-01-01), Roizman
patent: WO 9213943 (1992-08-01), None
patent: WO 9804726 (1998-02-01), None
Ho et al. (1996) Mol. Brain Res., vol. 41 (1-2), 200-209.*
Huard, J. et al.,Herpes simplex virus type 1 vector-mediated gene transfer to muscle, Gene Ther. 2(6):385-92 [Aug. 1995], Abstract only.
Barnettm F. H., Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7, Cancer Gene ther, 6(1):14-20 (Jan.-Feb. 1999). Abstract Only.
Bi, Wan Li et al., “In Vitro Evidence that Metabolic Cooperation is Responsible for the Bystander Effect Observed with HSV tk Retroviral Gene Therapy,” Human Gene Therapy, 4:725-731 (1993).
Bovintsis, E. J. et al., “Long-term survival of rats barb ring brain neoplasms treated with gancici vir and a herpes simplex virus vector that retains an intact thymidine kinase gene,” Cancer Res, 54(22):5745-51, (N v 15, 1994). Abstract Only.
Culver, Kenneth W., “Clinical Applications of Gene Therapy for Cancer,” Clinical Chemistry, vol. 40, N90. 4, pp. 510-512, (1994).
Doran, S. E. et al., “Gene expression from recombinant viral vectors in the central nervous system after blood-brain barrier disruption,” Neurosurgery, 36(5):965-70, (May 1995). Abstract Only.
Kramm, C. M. et al., “Herpes vector-mediated delivery of marker genes to disseminated central nervous system tum rs,” Hum Gene Ther, 7(3):291-300, (Feb 10, 1996). Abstract Only.
Kramm, C. M. et al., “Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy,” Hum Gene Ther, 8(17):2057-68, (Nov. 20, 1997). Abstract Only.
Kroll, R. A. et al., Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: a comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers, Neurosurgery, 43(4):879-86; discussion 886-9, (Oct. 1998). Abstract Only.
Markert, James M. et al., “Expanded spectrum of viral therapy int he treatment of nervous system tumors,” J. Neurosurg, 77:590-594 (1992).
Markert, James M. et al., “Reduction and Elimination of Encephalitis in an Experimental Glloma Therapy Model with Attenuated Herpes Simplex Mutants that Retain Susceptibility to Acyclovir,” Neurosurgery, vol. 32, No. 4, pp. 597-603, (Apr. 1993).
Martuza, Robert L., “Experimental Therapy of Human Gllomo by Means of a Genetically Engineered Virus Mutant,” Science, vol. 252, pp. 854-856 (May 10, 1991).
Mineta, Toshihiro et al., “Mutant Viral Therapy for Malignant Brain Tumors Using Ribonucleotide Reductase-Deficient Herpes Simplex Virus 1,” J. Neurosurg., vol. 80, No. 2, p. 381 (Feb. 10, 1994). Meeting Program Item #1534.
Moore, Alice E., “Effects of Viruses on Tumors,” Annual Review of Microbiology, vol. 8, pp. 393-410 (1954).
Moore, A. E., “The Oncolytic Viruses,” Experimental Tumor Research/Sloan-Kettering Institute for Cancer Research, 1:411-439, (1960).
Muldoon, L. L. et al., “Comparison f intercerebral inoculation and smotic blood-brain barrier disruption for delivery of adenovirus, herpesvirus, and iron oxide particles to normal rat brain,” Am J Pathol, 147(6):1840-51 (Dec. 1995). Abstract Only.
Nilaver,G. et al., “Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption,” Proc Natl Acad Sci U S A, 92(21):9829-33 (Oct. 10, 1995). Abstract Only.
Muldoon, L. L. et al., “A physiological barrier distal to the anatomic blood-brain barrier in a model of transvascular delivery,” AJNR Am J Neuroradiol, 20(2):217-22 (Feb. 1999). Abstract Only.
Neuwelt, E. A. et al., “Delivery of ultraviolet-inactivated 35S-herpesvirus across an osmotically modified blood-brain barrier,” J Neurosurg, 74(3):475-9 (Mar. 1991). Abstract Only.
Neuwelt, E. A. et al., “Delivery of virus-sized iron oxide particles to rodent CNS neurons,” Neurosurgery, 34(4):777-84 (Apr. 1994). Abstract Only.
Oldfield, Edward H. et al., Clinical Protocols, Gene Therapy for the Treatment of Brain Tumors Using Intra-Tumoral Transduction with Thymidine Kinase Gene and Intravenous Ganciclovir, Human Gene Therapy, 4:39-69 (1993).
Perng, G. C. et al.., “Evidence that the HSV-1 LAT's Main Role May be in Reactivation from Latency Rather than in Establishment of Latency,” Abstract presented at Association for Research in Vision and Opthalmology (ARVO) May 1997.
Perng, Guey-Chuen et al, “The Latency-Associated Transcript Gene of Herpes Simplex virus Type 1 (HSV-1) is Required for Efficient In Vivo Spontaneous Reactivation of HSV-1 from Latency,” Journal of Virology, vol. 68, No. 12, pp. 8045-8055 (Dec. 1994).
Perng, Guey-Chuen et al., “ An Avirulent ICP34.5 Deletion Mutant of Herpes Simplex virus Type 1 is Capable of In Vivo Spontaneous Reactivation,” Journal of Virology, vol. 60, No. 5, pp. 3033-3041 (May 1995).
Perng, Guey-Chuen et al., “High-Dose Oscular Infection with a Herpes Simplex Virus Type 1 ICP 34.5 Deletion Mutant Produces No Corneal Disease or Neurovirulence yet Results in Wild-Type Levels of Spontaneous Reactivation,” Journal of Virology, vol. 70, No. 5, pp. 2883-2893 (May 1996).
Rainov, N. G. et al. “Long-term survival in a rodent brain tumor model by bradykinin-enhanced intra-arterial delivery f a therapeutic herpes simplex virus vector,” Cancer Gene Ther, 5(3):158-62 (May-Jun. 1998). Abstract Only.
Rainov, N. G. et al. “Intraarterial delivery of adenovirus vectors and liposome-DNA complexes to experimental brain neoplasms,” Hum Gene Ther, 10(2):311-8 (Jan. 20, 1999). Abstract Only.
Rainov, N. G. et al., “A chimeric fusion protein f cytochrome CYP4B1 and green fluorescent protein for detection of pro-drug activating gene delivery and for gene therapy in malignant glloma,” Adv Exp Med Biol, 451:393-403 (1998). Abstract Only.
Rapoport, S. I., et al., “Tight-junctional modification as the basis of osmotic opening of the blood-brain barrier,” Ann N Y Acad Sci, 481:250-67 (1986). Abstract Only.
Yang, W. et al., “Enhanced delivery of boronophenylkalanine for neutron capture therapy by means of intracarotid injection and blood-brain barrier disruption,” Neurosurgery, 38(5):985-92 (May 1996), Abstract Only.
Rainov, N. G. et al., “Selective uptake of viral and monocrystalline particles de
Black Keith L.
Nesburn Anthony B.
Perng Guey-Chuen
Wechsler Steven L.
Yu John S.
Cedars-Sinai Medical Center
S. Wehbé Anne Marie
LandOfFree
Herpes simplex virus type 1 (HSV-1)-derived vector for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Herpes simplex virus type 1 (HSV-1)-derived vector for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Herpes simplex virus type 1 (HSV-1)-derived vector for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3415891